ValuEngine upgraded shares of Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) from a sell rating to a hold rating in a report released on Friday.

Navidea Biopharmaceuticals (NAVB) opened at 0.41 on Friday. The company has a market cap of $66.42 million and a P/E ratio of 0.85. Navidea Biopharmaceuticals has a 12-month low of $0.29 and a 12-month high of $1.16. The firm has a 50-day moving average price of $0.42 and a 200-day moving average price of $0.49.

Navidea Biopharmaceuticals (NYSEMKT:NAVB) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. Navidea Biopharmaceuticals had a negative return on equity of 65.90% and a negative net margin of 515.33%. The firm had revenue of $0.61 million during the quarter. On average, equities research analysts forecast that Navidea Biopharmaceuticals will post ($0.08) earnings per share for the current fiscal year.

WARNING: “Navidea Biopharmaceuticals Inc (NAVB) Lifted to “Hold” at ValuEngine” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/04/navidea-biopharmaceuticals-inc-navb-lifted-to-hold-at-valuengine.html.

Several hedge funds have recently modified their holdings of NAVB. Spark Investment Management LLC lifted its holdings in shares of Navidea Biopharmaceuticals by 17.6% in the 1st quarter. Spark Investment Management LLC now owns 494,000 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 74,000 shares during the period. HighTower Advisors LLC lifted its holdings in shares of Navidea Biopharmaceuticals by 7.2% in the 1st quarter. HighTower Advisors LLC now owns 177,966 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 11,900 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Navidea Biopharmaceuticals by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 4,887,743 shares of the biopharmaceutical company’s stock worth $2,492,000 after buying an additional 80,499 shares during the period. Finally, Virtu KCG Holdings LLC lifted its holdings in shares of Navidea Biopharmaceuticals by 305.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 336,414 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 253,471 shares during the period.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Navidea Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals Inc and related stocks with our FREE daily email newsletter.